Resverlogix (TSX:RVX) Net Income From Continuing Operations : C$-13.73 Mil (TTM As of Mar. 2024)

View and export this data going back to 2005. Start your Free Trial

What is Resverlogix Net Income From Continuing Operations?

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Resverlogix's net income from continuing operations for the three months ended in Mar. 2024 was C$1.81 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Mar. 2024 was C$-13.73 Mil.

Resverlogix Net Income From Continuing Operations Historical Data

The historical data trend for Resverlogix's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Resverlogix Net Income From Continuing Operations Chart

Resverlogix Annual Data

Trend

Apr14

Apr15

Apr16

Apr17

Apr18

Apr19

Apr20

Dec21

Dec22

Dec23

Net Income From Continuing Operations

Get a 7-Day Free Trial

-217.79

165.80

-31.71

-4.90

-22.46

Resverlogix Quarterly Data
	Apr19	Jul19	Oct19	Jan20	Apr20	Jul20	Oct20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Net Income From Continuing Operations	Get a 7-Day Free Trial															-7.05	-5.33	-6.02	-4.19	1.81

Resverlogix Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-13.73 Mil.

Resverlogix (TSX:RVX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Resverlogix Corp (TSX:RVX) » Definitions » Net Income From Continuing Operations

Comparable Companies

Traded in Other Exchanges

RVXCF:USA RFS:Germany

Address

4820 Richard Road South West, Suite 300, Calgary, AB, CAN, T3E 6L1

Website

https://www.resverlogix.com

Resverlogix Corp clinical-stage biotechnology company. The company is developing apabetalone (RVX-208), a first-in-class, small molecule that is a selective BET (bromodomain and extra terminal) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. Apabetalone is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. This selective inhibition of apabetalone on BD2 produces a specific set of biological effects with potentially important benefits for patients with chronic disease including cardiovascular disease (CVD) and associated comorbidities, and COVID-19.

Executives

Aaron Bradley Cann

Senior Officer

Resverlogix (TSX:RVX) Headlines

No Headlines